Pay in 4 interest-free payments of $6.19 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
No randomized controlled trials in human neurological disease exist for BPC-157 as of 2026
Later work examined NNMT inhibition combined with dietary changes in obese mice, reporting reductions in body weight, fat mass, and hepatic fat, alongside shifts in gut bacterial populations
Here's a real-world comparison of the weight loss data we have: Semaglutide 2.4 mg (Wegovy): ~15% body weight loss at 68 weeks in the STEP 1 trial Tirzepatide 15 mg (Zepbound): ~22.5% body weight loss at 72 weeks in SURMOUNT-1 Retatrutide 12 mg: ~24.2% body weight loss at 48 weeks in Phase 2 (shorter trial, remember) Promising, but still unproven at scale
How good are they
Additionally, GIP is suggested to regulate glucose homeostasis by stimulation of pancreatic alpha cells to secrete glucagon during euglycemia and hypoglycemia (17)
US$ 20.29
US$ 26.18
US$ 20.71
US$ 24.05
US$ 28.11
US$ 24.74
US$ 22.42
